Literature DB >> 23379638

Liraglutide effective in the severely insulin-resistant patient with type 2 diabetes requiring U-500 insulin: a case report.

Kevin M Pantalone1, Charles Faiman.   

Abstract

BACKGROUND/
OBJECTIVE: We describe the effectiveness of liraglutide therapy in a severely insulin-resistant patient with type 2 diabetes mellitus (DM-2) requiring U-500 insulin. SUBJECT AND METHODS: A 65-year-old morbidly obese man (body mass index, 67.3 kg/m(2); weight, 156.2 kg) presented with a 20-year history of DM-2; the glycemic control deteriorated to U-500 insulin requirement. He was inadequately controlled (hemoglobin A1c [HbA1c], 9.1%) on metformin plus U-500 insulin titrated to 575 units daily. Liraglutide was added and titrated to 1.8 mg once daily over 3 weeks.
RESULTS: Insulin requirements decreased markedly (>50%) to 250 units daily after 5 months of added liraglutide, with a concurrent improvement in HbA1c from 9.1% to 6.9% and weight loss of 22.6 kg.
CONCLUSIONS: The addition of once-daily liraglutide to the regimen of patients with uncontrolled DM-2 requiring U-500 insulin should be considered as it may help to reduce insulin requirements, improve glycemic control, and assist with weight management.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23379638     DOI: 10.1089/dia.2012.0328

Source DB:  PubMed          Journal:  Diabetes Technol Ther        ISSN: 1520-9156            Impact factor:   6.118


  4 in total

1.  Use of Premixed Insulin, Metformin, and a Glucagon-Like Peptide 1 Receptor Agonist as a Therapeutic Approach for Uncontrolled Type 2 Diabetes.

Authors:  Nicole Ehrhardt; Sasan Fazeli; Sanjana Rao; Richard Amdur
Journal:  Diabetes Spectr       Date:  2020-05

2.  Initiation of human regular U-500 insulin use is associated with improved glycemic control: a real-world US cohort study.

Authors:  Elizabeth L Eby; Bradley H Curtis; Steven C Gelwicks; Robert C Hood; Iskandar Idris; Anne L Peters; Richard M Bergenstal; Jeffrey A Jackson
Journal:  BMJ Open Diabetes Res Care       Date:  2015-04-30

3.  Glucagon-like peptide-1 analogues - an efficient therapeutic option for the severe insulin resistance of lipodystrophic syndromes: two case reports.

Authors:  Joana Oliveira; Eva Lau; Davide Carvalho; Paula Freitas
Journal:  J Med Case Rep       Date:  2017-01-13

4.  ADDITION OF DULAGLUTIDE FOR A HIGH-DOSE INSULIN REQUIRING PATIENT WITH TYPE 2 DIABETES MELLITUS: A REMARKABLE RESPONSE.

Authors:  Mehrunissa Kazim; Nitin Trivedi
Journal:  AACE Clin Case Rep       Date:  2018-11-01
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.